With recent advances in high-throughput SNP typing technologies, genome-wide association studies have become a realistic approach to identify the causative genes that are responsible for common diseases of complex genetic traits. In this strategy, a tradeoff between the increased genome coverage and a chance of finding SNPs incidentally showing a large statistics becomes serious due to extreme multiple-hypothesis testing.
Introduction
Genome-wide association studies have been proposed as a strategy to identify genetic factors with small to moderate genetic effects in the development of human diseases, as typically assumed for a common disease common variant (CDCV) model (1) . In this strategy, a disease-associated locus is identified through single nucleotide polymorphisms (SNPs) that show 'significantly' different allele frequencies between affected (cases) and unaffected (controls) individuals, and a large number of SNPs are tested for association in an attempt to realistically identify such SNPs (2, 3) . Although only a theoretical perspective a decade ago (1) , with the unprecedented advance in largescale genotyping technologies (4) (5) (6) , it has now become a realistic approach to exploring the genetic basis of human disease (7, 8) . In addition, recent efforts in the International HapMap Project to understand the genetic diversity among human populations (9, 10) , have greatly contributed to clarifying the extent to which the number of marker SNPs could be reduced to achieve given genome coverage, or how much genome coverage can be obtained with a given marker SNP set by optimally 'tagging' untyped SNPs based on the linkage disequilibrium (LD) observed in the human genome (11) (12) (13) (14) (15) (16) ).
Meanwhile, the major interest of the most researchers who plan genetic association studies, would be the practical success rates in such attempts and their efficient study designs, rather than mere genome coverage (17, 18) , because increase in genome coverage might not be linearly translated into gain in power (19, 20) . In addition, the more SNPs are genotyped to achieve better genome coverage, the higher hurdle is imposed for a target allele to be detected.
. This dilemma, know as the trade-off between increased genome coverage and the consequent inflation of null statistics due to extreme multiple testing, is a unique feature of genetic association studies, and is best described by considering the distributions of test statistics for markers truly associated with a causative allele ("causal distribution") and for all other markers ("null distribution") (21) . Regardless of the properties of the causative SNP and whether one or more tagging strategies are used, the null distribution for a given marker set depends on its genome coverage in the study population. In particular, the null distribution with complete genome coverage is related to the overall diversity of the human genome and should substantially shift to the right (7, 8, 22) . On the other hand, for a given disease model, the size of the test statistic expected for the causative SNPs is limited by the number of samples to be analyzed, once they are directly captured by one or more marker SNPs. After all, the feasibility of genome-wide association studies, or the required sample size to obtain realistic power, is determined by the overall diversity of the human genome, or given restricted study resources, the diversity of the human genome determines the property of disease-associated SNPs that can be detected with this approach.
Our questions are, therefore, how diverse is the human genome in view of conducting genome-wide association studies, how much power could be obtained to identify causative SNPs given that diversity, and how the typical study parameters affects the power in that situation? To answer these questions, we need to evaluate both null and causal distributions in a quantitative manner. Because both distributions intrinsically depend on the LD structure within N (typically >~10 [5] [6] ) interrelated marker SNPs and the particular location of causative SNPs within the genome, they cannot be calculated in an algebraic manner, but need to be estimated based on the observed data of human genome variations (10, 21) . So we approach these issues by extensively simulating a large number of case-control panels under both null and alternative scenarios based on the data from the International HapMap Consortiums (9, 10) , and assess the feasibility and efficient designs of whole genome association studies by estimating the genome-wide power that would be obtained using this genetic approach under varying study conditions.
Results
Estimation of null distributions of the maximum χ 2 statistics
In considering the issue of multiple testing in genetic association studies, it is convenient to evaluate the maximum value of the χ 2 statistic (max(χ 2 )) in all the marker SNPs that are truly unrelated to the causative SNP (21) . Different statistics can be used (23) (24) (25) (26) , but the power calculated for this statistic, i.e., the probability of max(χ 2 ) indicating a true association, will provide a reasonable bottom line to discuss the feasibility of typical genetic association studies (21) . When all N marker SNPs are independent, the null distribution for max(χ 2 ) is given as
is the cumulative density function of the χ 2 distribution (d.f.=1).
However, since SNPs in real marker sets are variably degenerated due to the presence of LD between adjacent SNPs, we empirically estimated the distribution of max(χ 2 ) for a series of marker sets by simulating 10000 null case-control panels, where each panel was generated by randomly resampling phased chromosomes from the HapMap data sets, and max(χ 2 ) was calculated for each case-control panel. Although the number of resampled chromosomes for each case-control panel (i.e., the sample size) does not significantly affect the distributions (data not shown), there arises some concern about the possibility of underestimating the null distributions due to resampling from very limited numbers of chromosomes, because the latter procedure could restrict the freedom of allelic segregation within the same chromosome. To address this issue, we progressively divided the whole genome into larger numbers of sub-blocks consisting of 10,000 to 10 SNPs in the HapMap Phase II set, and resampled these sub-blocks to simulate distributions of max(χ 2 ). Reducing the mean block size down to 7.1kb, these divisions allow for greater freedom of allelic segregation, but does not significantly affect the max(χ 2 ) distributions until the resampled block size becomes smaller than the mean LD length (27) , indicating that our simulations are not likely to substantially underestimate the null distributions (see Supplemental Fig. S1 ). Figure 1A shows the simulated null distributions in the CEU panel for varying numbers of randomly selected SNPs ("correlated" SNP sets). The number of segregating or polymorphic markers contained in each random set is designated as Ns.
The theoretical distribution for the same numbers (Ns) of "independent" SNPs, ) ( 2 Ns χ ϕ , is also provided (Fig. 1B) . The null distribution increases as the number of randomly selected SNP markers increases, and in a random 1000K set containing 681K segregating SNPs, the threshold χ 2 value that provides a genome-wide p value of 0.05 or 0.01 becomes as large as 27.6 or 30.5, respectively. On the other hand, reflecting the growing inter-marker LD intensity, the empirical distributions gradually deviate from the theoretical ones, ϕ Ns (χ 2 ) 's, for increasing Ns within the corresponding marker sets, underscoring the importance of considering inter-marker LD to avoid overestimation of the statistical threshold for multiple testing, especially for higher marker density.
Evaluation of the inter-marker LD
The intensity of the inter-marker LD in a given marker set is more simply evaluated by fitting the simulated distribution to a theoretical one for independent Nc makers, ϕ Nc (χ 2 ) (see Methods). Irrespective of marker sets, fitting is finely performed except in the vicinity of the maximal points (see Supplemental Fig. S2 ). In particular, the distribution in extreme χ 2 values is satisfactorily approximated to provide a rough estimate of the nominal p-value for given genome-wide thresholds as confirmed by the concordance of the upper p point in the simulated distribution with the upper p/Nc point in the χ 2 distribution (d.f.=1) (Bonferroni) ( Table 1 ). In this formulation, it is reasonable to regard Nc as the number of hypothetical independent SNPs equivalent to the corresponding marker set, where the null distribution for a large number of mutually degenerated SNPs is described by an integer and the mean intensity of the inter-marker LD is measured through the Nc/Ns ratio.
Nc values were calculated for a variety of randomly selected SNP marker sets and plotted against the number of segregating SNP markers therein (Fig. 1C) . As the Phase II data contain most of the SNPs in commercially available platforms, including Affymetrix® GeneChip® and Illumina® HumanHap® arrays (28) (29) (30) , Nc values were also evaluated for these platforms (see Supplemental Table 1 The SNPs on the Affymetrix® GeneChip® mapping array sets are degenerated to the same degree as random SNP sets, reflecting the fact that the SNPs on GeneChip® platforms are virtually randomly selected. In contrast, the SNPs on the Illumina® HumanHap300 are selected by efficiently tagging the HapMap Phase I SNPs in CEU, in which redundant SNPs are effectively eliminated (28) . As a result, degeneration in the HumanHap300 is substantially reduced compared to the corresponding random marker sets. In CEU, Nc for this 305.1K segregating SNP set (215K Nc) exceeds that for 417.8K segregating SNPs on GeneChip® 500K set (196K), as predicted by the higher genome coverage of the former set (see Table 1 and Supplemental Fig. S4 ). The tagging for CEU also increases the Nc in JPT+CHB, suggesting that tagging in one panel is also effective to a certain degree for another (31, 32) . The tagging seems to be less efficient in YRI, because the Nc value of HumanHap300® in YRI is less deviated from that of the random marker set with a corresponding Ns. In HumanHap550®, more tag SNPs are selected from YRI, which contributes to the relative increase in Nc for this marker set compared to that for the corresponding random marker SNP set. Nc/Nc G could also be used as another indicator of genome coverage of a given marker set.
Estimation of Nc for common
Causal distribution of max(χ 2 )
In view of power estimation, our next interest was the expected size of causal distributions relative to that of the inflated null distributions under varying disease/study parameters that affect the former distributions. To illustrate this, we simulated causal distributions of max(χ 2 ) for representative CEU alleles assumed to be causative (Fig. 2 ).
Two thousand case-control panels were generated for each simulation, in which phased
HapMap SNPs within 500Kb around the causative locus were randomly resampled assuming a multiplicative model with varying genotype relative risks (GRR) and the max(χ 2 ) was calculated for the resampled marker SNPs on GeneChip® 500K. and has a large GRR (>1.7) (Fig. 2, A , D, and G). In contrast, in the case where the causal allele with smaller MAF value (<0.2) or with a modest to weak GRR (<1.5) is to be detected, the trade-off between increased chance to capture the allele with higher r 2 using more markers and the accompanying cost of multiple testing can offset the power to varying degrees (Fig. 2, A Under strong genetic effects (GRR≧2.0) and large sample sizes (≧1500/arm), the power tends to saturate as the number of randomly selected SNPs increases (≧250K), because most of the common SNPs would be already captured by one or more marker SNPs with enough r 2 (see Supplemental Fig. S4 ), and the capture causes large shifts of causal distributions to the extent that the cost of multiple testing is trivial (Fig. 2) . On the other hand, when causative SNPs with weak to moderate genetic effects are detected with insufficient sample numbers, causal distributions cannot exceed large thresholds resulting from extreme multiple testing, even though more and more SNPs are captured by strong LD. With increasing effect size and sample number, the genome coverage is less influential except for smaller numbers of marker SNPs (<250K). The power gain obtained with increased genome-coverage tends to be offset by the increased cost of multiple testing. After all, in most scenarios, genome coverage is less influential on power when ≧250K random markers or equivalent tag SNPs are used. In contrast, the effect of sample numbers is predominant. To detect weak genetic effects (GRR≦1.3), the number of samples becomes critical. More than 4000 samples per arm will be required, but the requirement of genome coverage is not substantially increased when more than 250K randomly selected SNPs or their equivalents are used (Fig.3A) .
Given a higher genetic effect, this dependence on sample size is dramatically ameliorated, but the genome coverage remains less influential.
Power in different HapMap panels and in commercially available platforms
Power is significantly reduced in YRI compared to CEU and JPT+CHB for any marker set (Fig. 4A , B, and C). The lower power in YRI is mainly due to the lower (Fig. 4D ). HumanHap300®
shows comparable power to that of GeneChip® 500K, but the power of HumanHap300® is significantly reduced in YRI. In HumanHap550®, more tag SNPs from YRI and JPT+CHB were added to HumanHap300®, the power is more improved in YRI and in JPT+CHB, but the power is also increased to a lesser degree in CEU reflecting a transferability of tag SNPs between CEU and JPT+CHB. The power of various commercially available platforms with various sample sizes are shown in Figure   4E (adaptive threshold) and Supplemental Figure S7 (fixed threshold). Genome coverage and power of HumanHap550® in the CEU are comparable to those of the random 1000K set (see Supplemental Fig S4) , an equivalent to Human SNP Array 6.0®
that is planned by Affymetrix® (Fig. 4E) . Nevertheless, and in spite of the significant difference in cost, the gain of power in HumanHap550® is not so prominent. Also note that the power calculation for HumanHap550® could be slightly biased by using the subset of the Phase II SNPs as a reference.
Power depends on allele frequencies of causative alleles
Power strongly depends on MAF of causative alleles, and detecting rare causative alleles is very difficult (Fig. 2) and sample size (≧1000/arm) (Fig. 5) . In contrast, capturing rare causal SNPs (MAF<0.10) requires many more marker SNPs or their combinations than capturing common SNPs at the more cost of multiple hypothesis testing. Second, even when captured in high r 2 with one or more marker SNPs, associations with these rare SNPs are more difficult to detect than those with common SNPs (Fig.5) . In common diseases, the existence of multiple phenocopy variants would further compromise detection (multiple rare variants) (33, 34) . Thus, regardless of genome coverage, power is consistently lower for less common SNPs (Fig. 6A,C ). To detect rare causative SNPs, we need not only to invest in genotyping large numbers of marker SNPs with low MAF values by any means, but also to increase the sample size ( simulations, readers will easily evaluate the power and FPRP expected form given SNP set, sample size, and predicted effect size. As long as practical power (for example, 1-β >α) is obtained, FPRP is expected to less than 0.5, which will be satisfactory for initial discovery studies.
We estimated genome-wide thresholds based on the simulations using small numbers of HapMap chromosomes. In real studies, the threshold should be determined using their own applicable data sets, where diploid, rather than phased, chromosomes could be used when enough samples are analyzed. A larger number of chromosomes should contain more numbers of rare segregating SNPs, but these rare SNPs would not increase χ 2 thresholds substantially (22) .
In terms of the effective number of independent SNPs (Nc) in various marker sets, the diversity of the human genome is likely to be on the order of 1000K in CEU and the corresponding nominal p value giving a genome-wide α error of 0.05 is 5x10-8.
For moderate GRRs (≦1.5), this threshold could be overcome with ≦1500 samples per arm for very common SNPs (MAF>0.20), but for less common SNPs or those with a small genetic effect (GRR=1.1~1.2), extremely large numbers of samples will be required (Supplemental Figure S8) , which urges moves toward sharing typing data across multiple groups as exemplified in recent reports that identified predisposing factors with very modest genetic effects for type 2 diabetes (35-37). The diversity of our genome may not allow for detecting very rare causative alleles (<0.01) with even smaller genetic effects (i.e. GRR<1.1 using this approach (Fig.6D ),
Under these limitations, several issues should be considered to efficiently exploit study resources and to increase the chance of finding a true association. First, for the increased genome coverage to be effectively translated into power, it needs to be accompanied by a corresponding increase in sample size. When sample numbers are small relative to the effect size, the cost of multiple testing largely offsets the expected increase in the test statistics for causal alleles with no measurable gain in power, and can even exceed the gain in causal distributions (Fig. 4) . Increasing genome coverage with insufficient sample sizes would only consume resources with no substantial benefit in power. In addition, power tends to saturate in higher genome coverage and the effect of increasing the number of marker SNPs is less prominent compared to that of increasing sample sizes. In most simulated situations, more power is expected by doubling the sample size than by doubling the number of maker SNPs. For example, our simulations predict that doubling the sample size using GeneChip® Nsp 250K is almost certainly more efficient than analyzing half of the samples with both Nsp 250K + Sty 250K (see Supplemental Fig. S9 ).
The tagging strategy or statistical imputation is effective for increasing genome coverage with limited numbers of marker SNPs (21, 38, 39) , although it does not save the cost of multiple-hypothesis testing. The efficiency of generating a tag SNP set with higher genome coverage, however, is increasingly compromised. The additional gain in power becomes smaller with increasing genome coverage, while more and more effort will be required to find additional independent tag SNPs, because many SNPs are already captured by existing tag SNPs. In addition, we simulated power using "All
Phase II" set. In the sense that all references are captured through direct association, this marker set provides the ultimate coverage of the genome. Considering that modest increase of power using "All Phase II" set compared with random 1000K set (Fig. 3) , multimarker tagging presumably may not push up the power profoundly.
Transferability of a tag SNP set from one population to another is also a problem. Tag
SNPs for CEU are transferable to a certain degree to JPT+CEU, but they are less effective for YRI.
In any simulated scenarios, detecting SNPs with lower MAF values (0.05-0.10)
is very difficult using whole genome approaches, which is especially true for SNPs with less than 0.05 MAF values. In this situation, genome coverage to capture these rare SNPs becomes definitely important, but the required increase in the sample size is greater for rare SNPs than for common ones. Effort to devising SNP sets for these rare alleles, or exhaustive multimarker tests (21, 38) , is not likely to be rewarding unless their genetic effects are substantially large.
HapMap Data sets
The and is provided in three discrete sets ("all", "consensus", and "phased"), of which we used the former two sets for analysis. The "all" set contains the comprehensive data of all SNPs genotyped in each population including non-segregating sites, and the "consensus" set consists of the intersection of "all" sets from the three population panels.
The "all" sets contain 3755469, 3685205, and 3776850 SNPs for CEU, YRI, and JPT+CHB, respectively, and the "consensus" set includes 3535396 SNPs.
Marker sets and the references for power calculation
We generated a series of marker sets consisting of 10K, 30K, 50K, 125K, 250K, 500K, and 1000K SNPs, by randomly selecting SNPs from the Phase II "all" sets for each HapMap panel. The number of segregating SNPs in each set is denoted as Ns and shown in Table 1 , were fitted to the null distribution for hypothetical Nc independent SNPs, , by the least squares method as follows;
The Gnu Scientific Library was used to handle these functions.
Simulation of case-control studies and calculation of power
a single causative allele whose MAF and GRR are p ( ≥ 0.05) and γ, respectively.
Given the penetrance for AA, Aa, and aa genotypes as f AA , f Aa , and f aa , respectively, expected genotype frequencies in the case and control panels are given as, 
